MedTrace Logo

Preoperative Combined Radiochemotherapy for Patients With Rectal Carcinoma

NCT00297141 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-12-31

No results posted yet for this study

Summary

Rate of T-downstaging (Reduction of the T-stadium) at the time of final surgery following the preoperative combined radiochemotherapy (chemotherapy: Oxaliplatin, Capecitabine) Evaluation of the toxicity grade III and IV of the therapy scheme

Conditions

Interventions

DRUG

Capecitabine

chemotherapy oral use

DRUG

Oxaliplatin

chemotherapy intravenous use

Sponsors & Collaborators

  • Sanofi-Synthelabo

    collaborator INDUSTRY

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Austrian Breast & Colorectal Cancer Study Group

    lead NETWORK

Principal Investigators

  • Dietmar Oefner, MD · Austrian Breast & Colorectal Cancer Study Group

  • Alexander de Vries, MD · Austrian Breast & Colorectal Cancer Study Group

  • Josef Thaler, MD · Austrian Breast & Colorectal Cancer Study Group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-10-31
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00297141 on ClinicalTrials.gov